SCHEMBL6979328

SCHEMBL6979328

CCC(Cn1c(=O)[nH]c2ccccc2c1=O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.62
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 3/20 0.57
HPGD P15428 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
MAPK1 P28482 1/20 0.50
HSD17B10 Q99714 1/20 0.50
MPO P05164 2/20 0.49
ADORA3 P0DMS8 1/20 0.48
ADORA2A P29274 1/20 0.48
ADORA2B P29275 1/20 0.48
ADORA1 P30542 1/20 0.48
CA12 O43570 1/20 0.48
RNASEH1 O60930 1/20 0.48
ERCC1 P07992 1/20 0.48
ERCC5 P28715 1/20 0.48
FEN1 P39748 1/20 0.48
CA9 Q16790 1/20 0.48
ERCC4 Q92889 1/20 0.48
TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6983105 0.83 CYP1A2 (0.61) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL12862594 0.80 ALDH1A1 (0.73) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL9523849 0.78 CYP1A2 (1.00) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL8987555 0.77 CYP1A2 (0.65) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL6804934 0.77 CYP1A2 (0.65) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL8692730 0.75 CYP1A2 (0.76) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL7022854 0.73 CYP1A2 (0.59) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL6982894 0.73 HPGD (1.00) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL30877025 0.73 HPGD (1.00) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2
SCHEMBL14560539 0.73 ALDH1A1 (0.73) CYP1A2ALDH1A1KDM4EHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199530-A1 New compounds derived from quinazoline LES LABORATORIES SERVIER (FR) 2003-10-23 US disclosed
EP-1346992-A1 Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2003-09-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199530-A1 New compounds derived from quinazoline NQO2, XDH, DRD1 CYP1A2 105/4885ALDH1A1 331/4885KDM4E 4217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.